Report overview
Perhaps a more cost-effective option lies in developing vaccines using common cancer-associated antigens (CAAs), which in theory could treat a large number of tumours.
This report aims to provide a comprehensive presentation of the global market for Common Cancer-associated Antigens (CAAs) Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Common Cancer-associated Antigens (CAAs) Vaccine. This report contains market size and forecasts of Common Cancer-associated Antigens (CAAs) Vaccine in global, including the following market information:
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Common Cancer-associated Antigens (CAAs) Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tecemotide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Common Cancer-associated Antigens (CAAs) Vaccine include Seattle Genetics, Merck Serono, Merck KGaA, GlaxoSmithKline, KAEL-GemVax, SELLAS Life Sciences, Celldex and Immatics Biotechnologies, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Common Cancer-associated Antigens (CAAs) Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Common Cancer-associated Antigens (CAAs) Vaccine Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Segment Percentages, by Type, 2022 (%)
Tecemotide
Astuprotimut-R
Tertomotide
Nelipepimut-S
Others
Global Common Cancer-associated Antigens (CAAs) Vaccine Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Segment Percentages, by Application, 2022 (%)
Pediatrics
Adults
Global Common Cancer-associated Antigens (CAAs) Vaccine Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Common Cancer-associated Antigens (CAAs) Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Common Cancer-associated Antigens (CAAs) Vaccine revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Common Cancer-associated Antigens (CAAs) Vaccine revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Seattle Genetics
Merck Serono
Merck KGaA
GlaxoSmithKline
KAEL-GemVax
SELLAS Life Sciences
Celldex
Immatics Biotechnologies
Outline of Major Chapters:
Chapter 1: Introduces the definition of Common Cancer-associated Antigens (CAAs) Vaccine, market overview.
Chapter 2: Global Common Cancer-associated Antigens (CAAs) Vaccine market size in revenue.
Chapter 3: Detailed analysis of Common Cancer-associated Antigens (CAAs) Vaccine company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Common Cancer-associated Antigens (CAAs) Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
